Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

Disorders of the Skeletal Muscle

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...

Myocarditis I: Introduction

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Left atrial mechanical dispersion as a novel predictor biomarker of new-onset atrial arrhythmias in cardiac amyloidosis.

International journal of cardiology·2026

Same author

EACVI Survey on the Current Multi-Modality Imaging Practice in Patients with Tricuspid Regurgitation.

European heart journal. Imaging methods and practice·2026

Same author

Current Concepts in Pathogenesis and Conservative Management of Supraspinous Tendinopathies Using Shockwave Therapy-A Narrative Review of the Literature.

Biomedicines·2025

Same author

Real-World Case Series of Ravulizumab Use in Patients with Myasthenia Gravis in Romania.

Brain sciences·2025

Same author

A novel staging system of cardiac damage in aortic stenosis based on multi-chamber myocardial deformation.

European heart journal. Cardiovascular Imaging·2025

Same author

A Comparative Study of the Electroneurographic Findings in Amyloidotic Polyneuropathy in Patients with Light-Chain Amyloidosis and Glu54Gln Transthyretin Amyloidosis.

Medicina (Kaunas, Lithuania)·2025

Search research articles

Related Experiment Videos

Cardiac involvement in myasthenia gravis--is there a specific pattern?

C Călin¹, Oana Savu, Dafina Dumitru

¹Prof. Dr. C.C. Iliescu Institute of Cardiovascular Diseases, Bucharest, Romania.

Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne

|January 14, 2010

Summary

Myasthenia gravis can cause serious cardiac issues, including conduction disturbances and ECG changes. Early recognition and management of cardiovascular involvement are crucial for patient outcomes.

Related Experiment Videos

Area of Science:

Neurology
Cardiology
Autoimmune Disorders

Background:

Myasthenia gravis is an autoimmune neuromuscular disorder causing skeletal muscle weakness.
Cardiac involvement in myasthenia gravis presents diverse manifestations, from ECG abnormalities to sudden death.

Observation:

Two cases of myasthenia gravis with significant cardiovascular involvement are presented.
The first case involved symptomatic conduction disturbances and syncope requiring permanent pacing.
The second case exhibited ECG changes (giant diffuse T waves) in a patient with cardiovascular risk factors.

Findings:

Cardiovascular complications in myasthenia gravis require specialized cardiac care.
Differentiating etiology of conduction disturbances (disease vs. treatment) can be challenging.
ECG changes in myasthenia gravis necessitate further investigation and long-term monitoring.

Implications:

Highlights the importance of cardiac surveillance in myasthenia gravis patients.
Underscores the need for multidisciplinary approaches in managing complex cases.
Emphasizes the potential for significant cardiac morbidity in myasthenia gravis.